1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
53,08,800 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 110.63 | 75.38 | 69.05 |
| Total Income | 35.50 | 105.29 | 96.97 |
| Profit After Tax | 5.80 | 2.43 | 1.23 |
| NET Worth | 16.55 | 11.78 | 9.44 |
| Reserves and Surplus | 9.12 | 8.36 | 6.03 |
| Total Borrowing | 39.99 | 28.88 | 24.89 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹140.05 (+0.21%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹41.00 (+2.27%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹190.90 (+1.06%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹278.00 (+3.93%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹252.00 (+1.10%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹110.50 (-1.34%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹251.20 (+1.45%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹69.43 (-2.84%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹559.35 (-1.38%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,090.20 (+2.29%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,516.90 (+0.19%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹167.93 (+2.00%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.37 (+2.33%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Setting up of new manufacturing unit and unification of existing divisions | 15.00 |
| 2 | Working Capital Requirement | 15.00 |
| 3 | General Corporate Purposes |
About Amster Labs IPO
Incorporated in September 2014, Amster Labs Limited manufactures and distributes pharmaceutical products. The company offers a diverse range of pharmaceutical products, including ethical drugs, generic medications, and OTC solutions. The company's portfolio includes Softgel Capsules, Herbal Soft Gelatin Capsules, Carotenoids, and Calcitriol Soft Gelatin Capsules. They specialize in General & Beta Lactam Tablets, syrups, ointments, and powder injections for treatments such as anti-diabetic therapies, analgesics, antibiotics, and supplements. The company's manufacturing unit is situated in Baddi, Himachal Pradesh, covering an area of 75000 square feet. The company has ISO 9001:2015 and ISO 10002:2018 certifications to ensure product quality. As of March 31, 2024, there are 64 employees, all on payroll and none on contract. Competitive Strength: Experienced Promoters and Senior Management with extensive domain knowledge. Quality assurance and control. Investment in latest technology and maintain our edge in the market. Strong sales, marketing, and distribution capabilities. Large and rapidly growing R&D capabilities across our product portfolio. Strategic presence across the pharmaceu
Contact Details
Amster Labs Ltd. AddressSCO 166-167, Level 1,Sector 9C, Madhya Marg,Sector 9Chandigarh, Chandigarh, 1600090172-4183370cs@amsterlabs.inVisit Website